Nicotine and Mental Illness: Why Psychiatry Is Rethinking Abstinence
For decades, psychiatric practice treated smoking as a low-priority concern. Now, a growing movement argues that addressing nicotine dependence is as important as managing psychosis—and that harm reduction may be the most effective approach.
In psychiatric hospitals and community mental health centers across the country, a quiet revolution is underway. For decades, smoking was tolerated, facilitated, and sometimes encouraged in psychiatric settings—cigarettes were used as rewards for compliance, smoking areas were the primary social spaces, and addressing smoking was considered a low priority compared to managing psychosis, depression, or mania. That culture is changing. Driven by the stark mortality statistics—people with serious mental illness die 10–25 years earlier than the general population, primarily from smoking-related diseases—a growing movement within psychiatry is arguing that addressing nicotine dependence is as important as managing the primary psychiatric condition. And, controversially, that harm reduction—helping patients switch to non-combustible nicotine products when complete abstinence isn't achievable—may be the most effective approach for this population.
The mortality gap is the driving force behind psychiatry's rethinking of nicotine. People with schizophrenia, bipolar disorder, and severe depression die predominantly from cardiovascular disease, lung cancer, and COPD—diseases caused primarily by smoking, not by psychiatric illness or psychotropic medications. A person with schizophrenia who smokes loses more years of life to tobacco than to psychosis. The statistic has been known for decades, but it's only recently begun to drive changes in clinical practice. The shift reflects a broader recognition that mental health treatment must address the physical health of psychiatric patients—not just their psychiatric symptoms—and that smoking cessation is the single most impactful physical health intervention for this population. The days of psychiatrists ignoring their patients' smoking, on the grounds that 'they have bigger problems,' are ending.
The neurobiological basis of the mental-illness–smoking connection explains why cessation is so difficult for this population—and why harm reduction may be the most realistic approach. Nicotine acutely improves sensory gating (the brain's ability to filter irrelevant stimuli, which is impaired in schizophrenia), enhances cognitive function (attention, working memory, executive function—domains impaired in multiple psychiatric conditions), and has mood-elevating and anxiolytic effects. These are not placebo effects. They're pharmacologically real, mediated by nicotine's action on the same neurotransmitter systems (dopamine, norepinephrine, serotonin, acetylcholine) that psychiatric medications target. For a person with schizophrenia, a cigarette is a form of self-medication that partially compensates for neurobiological deficits that antipsychotics don't fully address. Asking them to quit without offering something that provides these same functions is asking them to surrender a coping mechanism that serves genuine, if maladaptive, needs.
The harm-reduction approach to nicotine in psychiatric populations follows the same logic as harm reduction in any population—but with greater force because the barriers to abstinence are higher and the consequences of continued smoking are more severe. For a psychiatric patient who's tried and failed to quit smoking multiple times, switching to a non-combustible nicotine product—vaping, nicotine pouches, or long-term NRT—eliminates the combustion products that cause the vast majority of smoking-related disease while maintaining the nicotine that serves genuine neurobiological and psychological functions. The approach is controversial within psychiatry (some clinicians view it as 'giving up' on abstinence) and within public health (some advocates view it as normalizing nicotine use in a vulnerable population). But the evidence increasingly supports it: studies of vaping as a harm-reduction intervention in psychiatric populations show quit rates that are substantially higher than those achieved by conventional cessation approaches, without worsening psychiatric symptoms.
The practical implementation of harm reduction in psychiatric settings faces significant barriers. Many psychiatric hospitals and residential facilities have gone smoke-free—a positive development for staff and non-smoking patients—but have implemented the policy without providing adequate alternatives for nicotine-dependent patients. The result is that patients experience forced nicotine withdrawal during hospitalization, often without access to NRT or other cessation support, in an environment that's already stressful and destabilizing. The smoke-free mandate, in these settings, is a policy without a program—a prohibition without a treatment plan. Implementing genuine harm reduction requires providing NRT and other nicotine alternatives systematically, training staff in cessation support, and creating environments where patients can manage their nicotine dependence safely rather than being forced into withdrawal.
The role of psychiatrists and mental health professionals in nicotine care needs to be redefined. Currently, most psychiatrists don't address smoking with their patients—it's considered outside their scope of practice, someone else's responsibility. But psychiatrists are the physicians who see psychiatric patients most frequently, who understand their neurobiology and their psychosocial circumstances, and who are best positioned to integrate nicotine care into psychiatric treatment. A model where psychiatrists screen for nicotine dependence, prescribe cessation pharmacotherapy (NRT, varenicline), provide brief counseling, and coordinate with cessation services—all within the context of the psychiatric treatment relationship—would reach a population that the current fragmented system systematically fails. The infrastructure for this model doesn't exist in most settings, but the components—training, reimbursement, referral pathways—can be built.
The rethinking of nicotine in psychiatry is part of a broader transformation in how the medical system approaches addiction. The recognition that nicotine dependence is a chronic, relapsing brain disease—not a 'bad habit' or a 'lifestyle choice'—has implications that extend beyond psychiatry to all of medicine. But psychiatry, because it serves the population with the highest smoking rates and the highest smoking-related mortality, is where the transformation is most urgent. The question is no longer whether psychiatrists should address their patients' nicotine dependence. It's how—and whether the tools they use will be the abstinence-only approaches that have failed this population for decades, or the harm-reduction approaches that the evidence increasingly supports. The psychiatric community is beginning to answer that question. The answer, increasingly, is harm reduction.
